Clinical Trial

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-18.
Trial Details
NCT Number NCT07313917
Lead Sponsor Longbio Pharma
Conditions Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrollment 150 participants
Start Date 2026-01-20
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06